Form 4: Director Gregory Bailey Acquires Serina Therapeutics Stock
Statement of Changes in Beneficial Ownership
Director Gregory Bailey acquired 59,667 shares of Serina Therapeutics common stock on March 31, 2026, for $1.94 per share, increasing his beneficial ownership.
Summary
- Director Gregory Bailey acquired 59,667 shares of Serina Therapeutics common stock on March 31, 2026.
- The acquisition was made at a price of $1.94 per share.
- These shares were issued as payment for accrued dividends on the reporting individual's Series A Convertible Preferred Stock, which was issued on April 8, 2025.
- Following this transaction, Mr. Bailey beneficially owns 126,910 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction related to dividend accrual rather than a strategic business development or financial performance update.
Positives
- Director Gregory Bailey increased his beneficial ownership of Serina Therapeutics common stock.
- The acquisition of shares was a result of accrued dividends, indicating potential value accumulation on preferred stock holdings.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, which details a change in beneficial ownership.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This specific filing indicates an increase in a director's stake, which can be interpreted in various ways by the market.
Stakeholder Impact
- Shareholders: Increased beneficial ownership by a director may be viewed positively as a sign of confidence in the company, or neutrally as a routine dividend payout.
- Management: The transaction reflects standard corporate procedures for handling accrued dividends on preferred stock.
Key Dates
| Date | Description |
|---|---|
| 04/08/2025 | Date of issuance of Series A Convertible Preferred Stock. |
| 03/31/2026 | Transaction date for the acquisition of common stock. |
| 04/21/2026 | Date of signature for the filing. |
Keywords
Serina Therapeutics, Form 4, SEC Filing, Stock Acquisition, Director, Beneficial Ownership, Common Stock, Series A Convertible Preferred Stock, Gregory Bailey
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.